Importantly, the combination of PI3K and CDK 4/6 inhibitors overcome intrinsic and adaptive resistance to PI3K inhibitors leading to tumor regression in PIK3CA mutant xenografts [85]. This evidence concerns the gene PIK3CA and neoplasm.